Amgen’s Uplizna shows promise in rare fibroinflammatory disease IgG4-RD

06 Jun 2024
pmlive.com
Clinical ResultPhase 3Drug Approval
Amgen’s Uplizna shows promise in rare fibroinflammatory disease IgG4-RD
Preview
Source: PMLiVE
Amgen has announced positive topline results from a late-stage trial evaluating Uplizna (inebilizumab-cdon) in immunoglobulin G4-related disease (IgG4-RD), a rare and progressive fibroinflammatory disease estimated to affect one to five per 100,000 people.
IgG4-RD impacts almost any organ in the body and is characterised by periods of remission and unpredictable disease flares.
The phase 3 MITIGATE trial has been comparing the CD19-targeted drug, which already holds approvals in several regions to treat the rare autoimmune disease neuromyelitis optica spectrum disorder, to placebo in adults with IgG4-RD.
The study met its primary endpoint, demonstrating a statistically significant 87% reduction in the risk of IgG4-RD flare compared to placebo during the 52-week placebo-controlled period.
All key secondary endpoints were also met, including annualised flare rate, and the overall safety results during the placebo-controlled period of the trial were consistent with the known safety profile of Uplizna.
Full data from the trial will be presented at a future medical meeting, Amgen said, adding that it is planning to file for approval of the drug in IgG4-RD in the US and “other key markets” based on the MITIGATE primary analysis results.
Jay Bradner, executive vice president, research and development, and chief scientific officer at Amgen, said: “MITIGATE is a landmark study with results that demonstrate an important advance in the treatment of patients with IgG4-RD, a devastating and rare disease that currently has no approved therapy.”
The trial also includes an optional three-year open-label treatment period, as well as a safety follow-up period after Uplizna discontinuation of up to two years.
Principal investigator, John Stone, Harvard Medical School and the Massachusetts General Hospital, described the data as a “major milestone for the IgG4-RD community”, adding that it provides “substantial insight into not only how [Uplizna] can help manage IgG4-RD, but also key insights into the nature of [the] condition”.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.